Effect of Gamified Sun Protection Education Provided to Chemotherapy Patients

September 4, 2026 updated by: Esra Turker, Lokman Hekim University

Effect of Gamified Sun Protection Education Provided to Chemotherapy Patients on Their Sun Protection Behaviors and Self-Efficacy

Chemotherapy may cause photosensitivity and other skin reactions that can negatively affect patients' comfort, quality of life, and adherence to treatment. Appropriate sun protection behaviors are therefore important for patients receiving chemotherapy.

This randomized controlled trial aims to evaluate the effect of gamified sun protection education on sun protection self-efficacy and sun protection behaviors in patients receiving chemotherapy.

A total of 54 patients will be randomly assigned to two groups, with 27 participants in each group. Participants in the intervention group will receive gamified sun protection education, while participants in the control group will receive usual care. The educational intervention will be delivered over a two-week period.

Sun protection self-efficacy and sun protection behaviors will be assessed at baseline and after completion of the two-week intervention.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye)
        • Lokman Hekim University Ankara Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Currently receiving chemotherapy
  • Aged 18 years or older
  • No major mental disorder that may interfere with participation in the study
  • No major visual, hearing, or communication impairment that may interfere with participation in the study
  • Able to read and write in Turkish
  • Willing to participate voluntarily in the study
  • Able to use mobile applications and a smartphone

Exclusion Criteria:

-Receiving radiotherapy concurrently with chemotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control group
Experimental: Intervention group
Behavioral: Gamified education
Gamified education

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sun Protection Self-Efficacy Scale Total Score
Time Frame: Baseline and immediately after completion of the 2-week intervention
Sun protection self-efficacy will be assessed using the Sun Protection Self-Efficacy Scale. The outcome will be the change in the total scale score from baseline to the end of the 2-week intervention. Higher scores indicate greater self-efficacy regarding sun protection behaviors.
Baseline and immediately after completion of the 2-week intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Sun Protection Behavior Scale Total Score
Time Frame: Baseline and immediately after completion of the 2-week intervention
Sun protection behaviors will be assessed using the Sun Protection Behavior Scale. The outcome will be the change in the total scale score from baseline to the end of the 2-week intervention. Higher scores indicate greater engagement in sun protection behaviors.
Baseline and immediately after completion of the 2-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lokman Hekim University

Collaborators

The Scientific and Technological Research Council of Turkey

Investigators

  • Principal Investigator: Esra Türker, Lokman Hekim University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 30, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

May 29, 2026

First Submitted That Met QC Criteria

September 4, 2026

First Posted (Actual)

September 10, 2026

Study Record Updates

Last Update Posted (Actual)

September 10, 2026

Last Update Submitted That Met QC Criteria

September 4, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2025328
  • 1919B012550663 (Other Grant/Funding Number: The Scientific and Technological Research Council of Turkey)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) are not planned to be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe